Monographie - Dacarbazine

Última actualización :
08/05/2024

Dacarbazine

Factores que influyen sobre la estabilidad

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Acocarb	México
Celdaz	India, Marruecos
Dabaz	India
Dacarb	India, Marruecos
Dacarba	India
Dacarbaz	Turquía
Dacarbazin	Austria, Hungría, Malasia, Polonia
Dacarbazina	Argentina, Chile, Colombia, Ecuador, España
Dacarbazine	Australia, Bélgica, Canadá, Dinamarca, Estados Unidos de América, Gran Bretaña, India, Irán, Irlanda, Nueva Zelanda, Suecia
Dacarex	India, Marruecos
Dacarin	India
Dacarpalm	Marruecos
Dacarzine	India
Dacatic	Finlandia
Dacin	Suiza
Dacmed	India
Daracina	Colombia
Deticene	Arabia Saudita, Francia, Grecia, Italia, Países Bajos, Túnez
Detilem	México
Detimedac	Alemania, Colombia
DTI	Malasia
DTIC	Australia, Austria, Estados Unidos de América, Gran Bretaña, Nueva Zelanda, Suecia
Fauldetic	Portugal
Ifadac	México
Oncocarbil	Argentina, Ecuador, Marruecos
Tiferomed	México

Bibliografía : Dacarbazine

	Tipo	Publicación
3	Periódico	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26	Periódico	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm 1997 ; 54: 915-920.
40	Periódico	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
57	Periódico	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Periódico	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Periódico	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Periódico	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Periódico	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
184	Periódico	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Periódico	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Periódico	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Periódico	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	Periódico	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Periódico	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Periódico	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
353	Periódico	Lunn G, Sansone EB. Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid. Am J Hosp Pharm 1987 ; 44: 2519-2524.
492	Periódico	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
860	Periódico	Nelson RW, Young R, Lamnin M. Visual incompatibility of dacarbazine and heparin. Am J Hosp Pharm 1987 ; 44: 2028.
905	Periódico	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1383	Periódico	Stevens MFG, Peatey L. Photodegradation of solutions of the antitumour drug DTIC. J Pharm Pharmacol 1978 ; 30: 47P.
1410	Periódico	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1501	Periódico	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1635	Periódico	El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F. Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. Am J Health-Syst Pharm 2002 ; 59: 1351-1356.
2107	Periódico	Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: 234-236.
3266	Laboratorio	Lipomed Laboratories Dacarbazine solutions: In Use stability of dacarbazine lipomed® Lipomed 2011
3267	Laboratorio	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3540	Laboratorio	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3605	Laboratorio	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010

Mentions Légales